Buy OraSure As Profitability Expectations Again Slide Forward, Says Canaccord
In a research note published today, Canaccord analyst Mark Massaro reiterated coverage with a “Buy” rating on OraSure Technologies (OSUR) and a price target of $11.00 as OSUR now expects to be EPS positive in Q2/14, six quarters ahead of Massaro prior expectations.
The analyst commented: “We view OSUR as one of our top picks given multiple drivers: various developments related to OraQuick HCV [AbbVie co-promotion agreement; Walgreen’s partnership; opportunity to expand partnerships w/ both pharma (OUS) and retail (US)]; accelerated push toward profitability from targeted spend on HIV OTC; and progress with Thermo in drugs-of-abuse”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Mark Massaro currently has a one-year average return of 9% and a 100% success rate. Massaro has a 11.7% average profit recommending OSUR, and he is ranked #2258 out of 3128 analysts.